761404-85-7

Basic information

• Product Name: Trityl olMesartan acid
• Synonyms: Trityl olMesartan acid;1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1-(triphenylMethyl)-1H-tetraz ol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-;4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid;4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylic acid;4-(1-Hydroxy-1-methylethyl)-2-propyl-1[4-[2-(trityltetrazol-5-yl)phenyl]phenyl]methylimidazol-5-sodium caboxylate;4-(2-Hydroxy-2-propanyl)-2-propyl-1-{[2'-(1-trityl-1H-tetrazol-5-yl)-4-biphenylyl]methyl}-1H-imidazole-5-carboxylic acid;Olmesartan impurity 11
• CAS NO: 761404-85-7
• Molecular Formula: C₄₃H₄₀N₆O₃
• Molecular Weight: 688.8161
• Mol File: 761404-85-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 901.0±75.0 °C(Predicted)
• Appearance: /
• Density: 1.22±0.1 g/cm3(Predicted)
• PKA: 2.39±0.50(Predicted)
• CAS DataBase Reference: Trityl olMesartan acid(CAS DataBase Reference)
• NIST Chemistry Reference: Trityl olMesartan acid(761404-85-7)
• EPA Substance Registry System: Trityl olMesartan acid(761404-85-7)

Safety Data

• Hazardous Substances Data: 761404-85-7(Hazardous Substances Data)

Usage

Description

Trityl olMesartan acid, with the chemical abstracts service number 761404-85-7, is an impurity found in olmesartan medoxomil, which is an anti-hypertensive medication used to treat high blood pressure.

Uses

Used in Pharmaceutical Industry:
Trityl olMesartan acid is recognized as an impurity in the production of olmesartan medoxomil. It is important to monitor and control the levels of this impurity to ensure the safety, efficacy, and quality of the final anti-hypertensive drug product. The presence of impurities like Trityl olMesartan acid can affect the pharmacokinetics, pharmacodynamics, and overall performance of the medication. Therefore, its management is crucial for maintaining the therapeutic benefits of olmesartan medoxomil in treating hypertension.

Synthetic route

ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({2'-[1-(triphenylmethyl)-1H-1,2,3,4-tetrazol-5-yl]-[1,1'-biphenyl]-4-yl}methyl)-1H-imidazole-5-carboxylate (144690-33-5) → 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7)

Conditions	Yield
With potassium hydroxide In N,N-dimethyl acetamide at 20℃; for 2h; Inert atmosphere;	98.11%
Stage #1: ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({2'-[1-(triphenylmethyl)-1H-1,2,3,4-tetrazol-5-yl]-[1,1'-biphenyl]-4-yl}methyl)-1H-imidazole-5-carboxylate With potassium hydroxide In isopropyl alcohol at 60℃; for 4h; Stage #2: With hydrogenchloride In water	90%
Stage #1: ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({2'-[1-(triphenylmethyl)-1H-1,2,3,4-tetrazol-5-yl]-[1,1'-biphenyl]-4-yl}methyl)-1H-imidazole-5-carboxylate With potassium hydroxide In water; isopropyl alcohol at 60℃; for 4h; Stage #2: With hydrogenchloride In water	90%

N-(triephenylmethyl)-5-<4'-(bromomethyl)-biphenyl-2-yl>tetrazole (124750-51-2) + ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate (144689-93-0) → ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({2'-[1-(triphenylmethyl)-1H-1,2,3,4-tetrazol-5-yl]-[1,1'-biphenyl]-4-yl}methyl)-1H-imidazole-5-carboxylate (144690-33-5) + 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) + C45H42N6O2

Conditions	Yield
With potassium phosphate In N,N-dimethyl acetamide at 60 - 65℃; for 6h; Solvent; Reagent/catalyst;	A 89.6% B 0.02% C 0.02%

N-(triephenylmethyl)-5-<4'-(bromomethyl)-biphenyl-2-yl>tetrazole (124750-51-2) → 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7)

Conditions	Yield
Multi-step reaction with 2 steps 1: potassium carbonate / N,N-dimethyl acetamide; acetone / 10 h / Reflux 2: potassium hydroxide / water; isopropyl alcohol / 4 h / 60 °C View Scheme
Multi-step reaction with 2 steps 1: potassium carbonate / acetone; N,N-dimethyl acetamide / 10 h / Reflux 2: potassium hydroxide / isopropyl alcohol / 4 h / 60 °C View Scheme
Multi-step reaction with 2 steps 1: lithium hydroxide / acetonitrile / 5 h / 70 - 75 °C / Autoclave 2: potassium hydroxide; water / 30 - 45 °C View Scheme

ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate (144689-93-0) → 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7)

Conditions	Yield
Multi-step reaction with 2 steps 1: potassium carbonate / N,N-dimethyl acetamide; acetone / 10 h / Reflux 2: potassium hydroxide / water; isopropyl alcohol / 4 h / 60 °C View Scheme
Multi-step reaction with 2 steps 1: potassium carbonate / acetone; N,N-dimethyl acetamide / 10 h / Reflux 2: potassium hydroxide / isopropyl alcohol / 4 h / 60 °C View Scheme
Multi-step reaction with 2 steps 1: lithium hydroxide / acetonitrile / 5 h / 70 - 75 °C / Autoclave 2: potassium hydroxide; water / 30 - 45 °C View Scheme

trityl chloride (76-83-5) + olmesartan → 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7)

Conditions	Yield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In water; acetone at 48 - 52℃; for 2h; Product distribution / selectivity;

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) + (1-adamantyl)carbonyloxymethyl halide → (1-adamantyl)carbonyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate (1304676-48-9)

Conditions	Yield
Stage #1: 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid With potassium carbonate; potassium iodide In N,N-dimethyl acetamide at 20℃; for 0.5h; Stage #2: (1-adamantyl)carbonyloxymethyl halide In N,N-dimethyl acetamide at 70℃; for 2h;	95.4%

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) + 1-chloroethyl cyclohexyl carbonate (99464-83-2) → 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({2'-[1-(triphenylmethyl)-1H-1,2,3,4-tetrazol-5-yl]-[1,1'-biphenyl]-4-yl}methyl)-1H-imidazole-5-carboxylate (1337980-10-5)

Conditions	Yield
With potassium carbonate; potassium iodide In N,N-dimethyl acetamide at 70℃; for 2h;	95%

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) + 4-chloromethyl-5-methyl-1,3-dioxol-2-one (80841-78-7) → trityl olmesartan medoxomil (144690-92-6)

Conditions	Yield
With potassium carbonate; potassium iodide In N,N-dimethyl acetamide at 0 - 45℃; for 3h; Inert atmosphere;	94%
Stage #1: 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid With potassium carbonate In N,N-dimethyl-formamide at 20℃; Autoclave; Stage #2: 4-chloromethyl-5-methyl-1,3-dioxol-2-one With potassium iodide In N,N-dimethyl-formamide at 20℃;	91.6%
With potassium carbonate; potassium iodide In acetone Product distribution / selectivity; Reflux;
In water; acetone at 48 - 52℃; for 5h; Product distribution / selectivity;
With potassium bromide In N,N-dimethyl acetamide at 15 - 50℃; for 8.6h; Time; Green chemistry;	23.2 g

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) + [1-(benzoyloxy)]ethyl halide → [1-(benzoyloxy)]ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate (1301629-88-8)

Conditions	Yield
Stage #1: 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid With potassium carbonate; potassium iodide In N,N-dimethyl acetamide at 20℃; for 0.5h; Stage #2: [1-(benzoyloxy)]ethyl halide In N,N-dimethyl acetamide at 70℃; for 2h;	88.9%

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) + [1-(cyclohexylcarbonyloxy)]ethyl halide → [1-(cyclohexylcarbonyloxy)]ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate (1304689-26-6)

Conditions	Yield
Stage #1: 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid With potassium carbonate; potassium iodide In N,N-dimethyl acetamide at 20℃; for 0.5h; Stage #2: [1-(cyclohexylcarbonyloxy)]ethyl halide In N,N-dimethyl acetamide at 70℃; for 2h;	88.2%

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) + 4-chloromethyl-5-methyl-1,3-dioxolan-2-one → trityl olmesartan medoxomil (144690-92-6)

Conditions	Yield
With potassium carbonate In N,N-dimethyl acetamide at 40℃; for 4h; Temperature;	76.9%

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) → C43H38N6O2 (761404-82-4)

Conditions	Yield
With benzotriazol-1-ol; 2-(2-Aminoethylamino)ethanol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In N,N-dimethyl-formamide at 60℃; for 5h;	75%

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) + tetradecanoyloxymethyl halide → tetradecanoyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate (1335030-67-5)

Conditions	Yield
Stage #1: 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid With potassium carbonate; potassium iodide In N,N-dimethyl acetamide at 20℃; for 0.5h; Stage #2: tetradecanoyloxymethyl halide In N,N-dimethyl acetamide at 70℃; for 2h;	75%

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) + octyl halide → octyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate (1254178-12-5)

Conditions	Yield
Stage #1: 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid With potassium carbonate; potassium iodide In N,N-dimethyl acetamide at 20℃; for 0.5h; Stage #2: octyl halide In N,N-dimethyl acetamide at 70℃; for 2h;	72%

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) + (1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)methyl halide → (1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate (1301629-90-2)

Conditions	Yield
Stage #1: 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid With potassium carbonate; potassium iodide In N,N-dimethyl acetamide at 20℃; for 0.5h; Stage #2: (1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)methyl halide In N,N-dimethyl acetamide at 70℃; for 2h;	68.3%

6-nitrohexan-1-amine (132124-24-4) + 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) → C49H52N8O4 (1254178-06-7)

Conditions	Yield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In N,N-dimethyl-formamide at 20℃; for 6h;	60%

7-aminoheptanoic acid ethyl ester (1117-66-4) + 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) → C52H57N7O4 (1254178-08-9)

Conditions	Yield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In N,N-dimethyl-formamide at 20℃; for 6h;	55%

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) → octyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate (1254178-26-1)

Conditions	Yield
Multi-step reaction with 2 steps 1.1: potassium carbonate; potassium iodide / N,N-dimethyl acetamide / 0.5 h / 20 °C 1.2: 2 h / 70 °C 2.1: hydrogenchloride / water; acetone / 2 h / 20 °C 2.2: pH 4 - 5 View Scheme

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) → (1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate (1301629-91-3)

Conditions	Yield
Multi-step reaction with 2 steps 1.1: potassium carbonate; potassium iodide / N,N-dimethyl acetamide / 0.5 h / 20 °C 1.2: 2 h / 70 °C 2.1: hydrogenchloride / water; acetone / 2 h / 20 °C 2.2: pH 4 - 5 View Scheme

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) → [1-(cyclohexylcarbonyloxy)]ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate (1304689-27-7)

Conditions	Yield
Multi-step reaction with 2 steps 1.1: potassium carbonate; potassium iodide / N,N-dimethyl acetamide / 0.5 h / 20 °C 1.2: 2 h / 70 °C 2.1: hydrogenchloride / water; acetone / 2 h / 20 °C 2.2: pH 4 - 5 View Scheme

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) → (1-adamantyl)carbonyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate (1304676-50-3)

Conditions	Yield
Multi-step reaction with 2 steps 1.1: potassium carbonate; potassium iodide / N,N-dimethyl acetamide / 0.5 h / 20 °C 1.2: 2 h / 70 °C 2.1: hydrogenchloride / water; acetone / 2 h / 20 °C 2.2: pH 4 - 5 View Scheme

4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(1-(triphenylmethyl)tetrazol-5-yl)phenyl)phenyl)methylimidazole-5-carboxylic acid (761404-85-7) → [1-(benzoyloxy)]ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate (1301629-89-9)

Conditions	Yield
Multi-step reaction with 2 steps 1.1: potassium carbonate; potassium iodide / N,N-dimethyl acetamide / 0.5 h / 20 °C 1.2: 2 h / 70 °C 2.1: hydrogenchloride / water; acetone / 2 h / 20 °C 2.2: pH 4 - 5 View Scheme

Upstream product

• 124750-51-2 N-(triephenylmethyl)-5-<4'-(bromomethyl)-biphenyl-2-yl>tetrazole 
• 144689-93-0 ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate 
• 76-83-5 trityl chloride 
• 144690-33-5 ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({2'-[1-(triphenylmethyl)-1H-1,2,3,4-tetrazol-5-yl]-[1,1'-biphenyl]-4-yl}methyl)-1H-imidazole-5-carboxylate 

Downstream Products

• 144690-92-6 trityl olmesartan medoxomil 
• 1254178-26-1 octyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1301629-91-3 (1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1304689-27-7 [1-(cyclohexylcarbonyloxy)]ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1304676-50-3 (1-adamantyl)carbonyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1301629-89-9 [1-(benzoyloxy)]ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1301629-90-2 (1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1304676-48-9 (1-adamantyl)carbonyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1301629-88-8 [1-(benzoyloxy)]ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1304689-26-6 [1-(cyclohexylcarbonyloxy)]ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1254178-12-5 octyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 1335030-67-5 tetradecanoyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(1-trityltetrazol-5-yl)phenyl]phenylmethyl}imidazole-5-carboxylate 
• 144689-63-4 olmesartan medoxomil 
• 1337980-10-5 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({2'-[1-(triphenylmethyl)-1H-1,2,3,4-tetrazol-5-yl]-[1,1'-biphenyl]-4-yl}methyl)-1H-imidazole-5-carboxylate 

Relevant articles and documents

A high purity of the preparation process of trityl olmesartan medoxomil

The invention discloses a preparation method of a triphenyl methyl olmesartan intermediate compound I. The method comprises the steps of a) hydrolyzing a compound II in the presence of alkali to generate a compound III; b) performing a condensation reaction on the compound III and a compound IV in the presence of a catalyst to prepare a compound I; c) adding water in the step b), and then extracting by using a halogenated hydrocarbon solvent system; d) concentrating the compound I obtained in the step c). The equation is as shown in the specification. The preparation method disclosed by the invention is mild in reaction conditions, small in by-products, high in purity of final products and high in yield; the preparation process is environment-friendly, and is low in wastewater production and beneficial in industrial mass production.

Method of Producing Related Substance of Olmesartan Medoxomil

PURPOSE: A method for preparing a related substance of olmesartan medoxomil is provided to control particle size and to enable easy preparation. CONSTITUTION: A method for preparing a related substance of olmesartan medoxomil comprises: a step of reacting ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazole-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate with lithium hydroxide to prepare 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazole-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate in a mixture solvent of water and dioxane; and a step of reacting the prepared compound with ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazole-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate under the presence of tetrahydro furane and benzene sulfonic acid.

Preparation method of key intermediate of olmesartan medoxomil and olmesartan medoxomil

The invention relates to a preparation and refinement method of a key intermediate of olmesartan medoxomil and the olmesartan medoxomil, and belongs to the technical field of medicine. The structural formula of the olmesartan medoxomil is shown as a formula I (Please see the specification).